Precision science. Pioneering medicine. Patient driven.
The Woodlands, TX
Joined July 2016
- Tweets411
- Following26
- Followers637
- Likes44
Today, we reported Q2 2026 financial results and shared updates on key milestones. We're proud of the progress we're making in our mission to transform patients' lives through innovative medicines. Learn more: bit.ly/4xg72DU
Join us on August 6 as we report Lexicon’s Q2 2026 financial results. Tune in to our live conference call and webcast at 8:30 a.m. ET. For details: bit.ly/4hCuUgf
We’re joining the @HeartinDiabetes CME Conference in Philadelphia with the Metabolic Endocrine Education Foundation. These conversations are critical for translating science into clinical practice, especially in HCM. #HID26
This week, we’re heading to #ADASciSessions in New Orleans! This year, we’ll share data from our clinical programs in type 1 diabetes and diabetic peripheral neuropathic pain. Learn more: lexpharma.com/media-center/n…
We’ll be in NYC for the @Jefferies Healthcare Conference next week, meeting with the healthcare investment community and sharing updates on Lexicon’s work across cardiometabolic disease. For more: investors.lexpharma.com/news… #JefferiesHealthcare
Painful diabetic peripheral neuropathy affects an estimated 30% of those with type 1 diabetes and 50% of those with type 2 diabetes. Following #PeripheralNeuropathyAwarenessWeek, we’re continuing to elevate patient voices and advance research for unmet needs.
We’re participating in the @HCWCO BioConnect Investor Conference this week! Lexicon management will join a fireside chat on May 19 at Nasdaq HQ in NYC. For more: investors.lexpharma.com/news… #HCWConference
This weekend at #ESCCongress, Lexicon will present data from a new SCORED trial analysis exploring heart failure outcomes across cardiac biomarkers.
Our Q1 2026 results reflect continued progress across our cardiometabolic and pain pipeline – supporting our focus on advancing programs with the potential to make a meaningful difference for people with unmet needs.
Learn more: investors.lexpharma.com/news…
Lexicon will report Q1 2026 financial results next week on May 7. Live call & webcast details can be found here: investors.lexpharma.com/news…
Glad to be at AAN 2026 this year, where Lexicon shared Phase 2b PROGRESS results supporting a 10 mg dose for Phase 3 development in DPNP, along with new preclinical data. Learn more: investors.lexpharma.com/news… #AANAM
HCMA sat down with Dr. Ahmad Masri recently to discuss the latest clinical trials in HCM - including the SONATA-HCM Phase 3 study of Lexicon’s dual SGLT1/SGLT2 inhibitor - and the evolving HCM research landscape.
Listen to the episode here: youtube.com/watch?v=P867KtPS…
We’re heading to Chicago for the #AAN Annual Meeting! Lexicon will be onsite engaging with the neurology community and our SVP of Discovery, Suma Gopinathan, PhD, will lead two presentations on our investigational AAK1 inhibitor. Learn more: index.mirasmart.com/AAN2026/… #AANAM
We were pleased to sponsor and join industry peers at the 2026 Texas Life Sciences Summit, connecting with leaders and innovators helping shape the future of life sciences. We left encouraged by the momentum across the industry and energized about the opportunities ahead!
New insights from #ACC26. Dr. Juan Badimon shared Chapter 2 data from the SOTA‑P‑CARDIA trial, building on prior findings in people with HFpEF. Watch the presentation: reachmd.com/clinical-practic…
We’re heading to @ACCinTouch this week, where data from Lexicon’s clinical programs will be presented in oral and poster sessions, including analyses from the SCORED and SOTA‑P‑CARDIA studies. Learn more: investors.lexpharma.com/news…
Chronic pain, including DPNP, doesn’t get the attention it deserves. Dr. Webster’s article advances the conversation on expanding treatment options. He previously joined Lexicon’s Chronic Pain Roundtable on non‑opioid innovation. Read more: painnewsnetwork.org/stories/…
